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Abstract
Introduction: Early treatment of rheumatoid arthritis (RA) has been shown to retard the development of joint damage 
for a period of up to 5 years. The aim of this study was to evaluate the radiologic progression beyond that time in 
patients with early RA initially treated with a combination of three disease-modifying antirheumatic drugs (DMARDs) or 
a single DMARD.
Methods: A cohort of 199 patients with early active RA were initially randomized to receive treatment with a 
combination of methotrexate, sulfasalazine, and hydroxychloroquine with prednisolone (FIN-RACo), or treatment with 
a single DMARD (initially, sulfasalazine) with or without prednisolone (SINGLE). After 2 years, the drug-treatment 
strategy became unrestricted, but still targeted remission. The radiographs of hands and feet were analyzed by using 
the Larsen score at baseline, 2, 5, and 11 years, and the radiographs of large joints, at 11 years.
Results: Sixty-five patients in the FIN-RACo and 65 in the SINGLE group had radiographs of hands and feet available at 
baseline and at 11 years. The mean change from baseline to 11 years in Larsen score was 17 (95% CI, 12 to 26) in the 
FIN-RACo group and 27 (95% CI, 22 to 33) in the SINGLE group (P = 0.037). In total, 87% (95% CI, 74 to 94) and 72% (95% 
CI, 58 to 84) of the patients in the FIN-RACo and the SINGLE treatment arms, respectively, had no erosive changes in 
large joints at 11 years.
Conclusions: Targeting to remission with tight clinical controls results in low radiologic progression in most RA 
patients. Patients treated initially with a combination of DMARDs have less long-term radiologic damage than do those 
treated initially with DMARD monotherapy.
 Trial registration : Current Controlled Trials ISRCTN18445519.
Introduction
Conservatively treated cohorts of rheumatoid arthritis
(RA) patients have shown a constant deterioration of
joint integrity [1,2]. However, treatment with traditional
disease-modifying antirheumatic drugs (DMARDs) alone
or in combinations [3,4] with glucocorticoids [5] as well
as with biologic agents [6-9] has been shown to retard the
progression of joint damage. Early therapy with combina-
tions of conventional DMARDs has been shown to retard
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years [4,10], but the effects of initial aggressive DMARD
therapy on radiologic prognosis after that are unknown.
We previously demonstrated that early RA patients
treated with a combination of DMARDs (methotrexate,
sulfasalazine, and hydroxychloroquine with predniso-
lone) reached, at 2 years, more often clinical remission [3]
and had less radiographic progression at 2 years [3] and at
5 years [10] than did patients initially treated with a single
DMARD. We also reported that, at 11 years, most
patients in both treatment groups had low disease activity
and well-preserved function, but the combination
DMARD-group patients reached remission more often
than did those treated initially with a single DMARD [11].
In this study, we explored the effects of initial treatment




From April 1993 to May 1995, 199 DMARD-naïve
patients with recent-onset RA were admitted to this ran-
domized study comparing the efficacy and tolerability of
treatment with either a combination of DMARDs (start-
ing with methotrexate, sulfasalazine, and hydroxychloro-
quine with prednisolone; FIN-RACo strategy) or a single
DMARD (initially sulfasalazine with or without predniso-
lone; SINGLE strategy). The treatment was targeted
toward remission in all patients. After 2 years, the treat-
ment of RA was unrestricted, but still aiming at remis-
sion. Thus, regardless of the original randomization
group, the patients could be treated liberally with
DMARDs, biologic agents, glucocorticoids, and with
their combinations, as clinically indicated and tolerated.
Conversely, in long-term remission the protocol required
drug doses to be reduced and eventually tapered off. The
patient-selection criteria and the study design were
described in detail earlier [3,10,11].
Radiologic assessment
Hands and feet of all patients were radiographed at base-
line and at 2, 5, and 11 years. Hip, knee, elbow, and shoul-
der joints of the patients were radiographed at 11 years in
13 study centers; in two study centers, only clinically
symptomatic large joints were radiographed. Total joint
replacements were counted from the radiographs as well
as from the patients' medical records. The radiographs
were assessed by the same experienced radiologist (LL),
who was blinded to the clinical data but aware of the
order of the radiographs. The radiographs of hands and
feet were scored according to the method of Larsen et al.
[12], with a range from 0 to 200. The large joints were also
scored according to the method of Larsen [12], and a
score of ≥2 was considered to indicate erosive disease.
Clinical assessments were performed by the treating
rheumatologist. DMARD strategies used between years 2
and 11 were carefully elucidated based on the patient's
self-report and his or her medical records [11].
Ethical considerations
The study was performed according to the principles of
the Declaration of Helsinki. The protocol was approved
by the national health authorities and ethics committees
in all 18 participating hospitals. All patients gave written
informed consent.
Statistical methods
The data are presented as means with standard devia-
tions (SDs), medians with interquartile ranges (IQRs), or
counts with percentages. Statistical comparison between
groups was made by t test, permutation test, χ2 test, or the
Fisher Exact test, when appropriate. The 95% confidence
intervals (95% CIs) for the Larsen score are obtained by
bias-corrected bootstrapping due to the skewed distribu-
tion. The difference in crude changes in Larsen score
between the groups was tested by a permutation test. A
random coefficient model with bootstrapped standard
errors was adapted to analyze the progression of the Lar-
sen score during 11 years and to compare the groups in
time. An ordered logistic regression analysis was used to
estimate the prediction of achieving radiologic progres-
sion. The adjusted risk ratio (RR) between the groups for
having no erosive changes in large joints was estimated by
a generalized linear model (log link), with presence of
erosion in hands or feet at baseline as covariate. A time-
to-event analysis based on the product-limit estimate of
the cumulative "survival" function (Kaplan-Meier) was
used to describe the time to the first total joint replace-
ment. A log-rank test was used to identify any survival
difference between the groups.
Results
Of the 199 patients originally randomized to the study,
195 started treatment, 97 in the FIN-RACo group, and
98, in the SINGLE group. At the 11-year visit, 68 patients
were assessed in the FIN-RACo group, and 70, in the
SINGLE group; the patients' baseline demographic and
clinical characteristics were comparable [11]. In total, 130
patients had radiographs of hands and feet available at
baseline and at 11 years, 65 cases in each group.
A trend toward a higher mean (range) Larsen score at
baseline was found in the SINGLE group compared with
the FIN-RACo group: 5 (0 to 30) versus 3 (0 to 25) (P =
0.069). Furthermore, the dropout cases in the FIN-RACo
group had a higher mean ± SD Larsen score at baseline
than did the completers: 6 ± 9 versus 3 ± 6 (P = 0.037). In
the SINGLE group, the baseline Larsen scores did not dif-
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5 ± 7 (P = 0.22).
The cumulative percentages of Larsen scores in both
groups are shown in Figure 1. One outlier in the FIN-
RACo group had progressed to almost a maximum score
after 11 years. Despite active combination DMARD treat-
ment, this patient had had high disease activity and HAQ
score throughout the follow-up, and by 11 years, also had
damage in large joints as well as one total joint replace-
ment.
The mean Larsen scores of hands and feet at baseline
and at 2, 5, and 11 years in both groups are shown in Fig-
ure 2. The crude mean change from baseline to 11 years
in Larsen score was 17 (95% CI, 12 to 26) in the FIN-
RACo group and 27 (95% CI, 22 to 33) in the SINGLE
group (P = 0.037). When using all time points (0, 2, 5, and
11 years) and adjusting for Larsen score at baseline, the
progression of Larsen score differed statistically signifi-
cantly between the groups (P = 0.021, for Time-by-Group
interaction effect), with the FIN-RACo group having on
average lower progression (P < 0.001, for Group-Effect)
(Figure 2a). In an ordered logistic regression analysis, the
extent of joint-damage progression in hands and feet at
11 years was predicted by the presence of serum rheuma-
toid factor at baseline and by the single-treatment strat-
egy for the first 2 years (Table 1).
The crude mean change from baseline to 11 years in
Larsen score was 10 (95% CI, 6 to 16) in patients who had
been in remission at 1 year and 25 (95% CI, 21 to 31) in
patients who had not been in remission at 1 year (P =
0.001). When using all time points (0, 2, 5, and 11 years)
and adjusting for Larsen score at baseline, the progres-
sion of Larsen score differed statistically significantly
between the patients in remission and not in remission at
1 year (P < 0.001, for Time-by-Group interaction effect),
with the patients in remission at 1 year having on average
lower progression (P < 0.001, for Group-Effect) (Figure
3).
At 11 years, 52 and 54 patients in FIN-RACo and in
SINGLE groups, respectively, had all the large joints
radiographed. In FIN-RACo and SINGLE groups, 87%
(95% CI, 74 to 94) and 72% (95% CI, 58 to 84), respec-
tively, of these patients had no erosive changes in large
joints at 11 years (RR, 1.22 (95% CI, 0.99 to 1.50)). The
number of damaged large joints (Larsen score, ≥2) did
not differ between the groups (Table 2).
Nine patients (four in the FIN-RACo and five in the
SINGLE group) had altogether 12 total joint replace-
ments (six knees and six hips). Of these, two arthro-
plasties had been performed because of primary
osteoarthrosis of the knee, and one, because of hip frac-
ture. The occurrence of total joint replacements did not
differ between the FIN-RACo and the SINGLE treatment
groups: 6% (95% CI, 2 to 16) versus 8% (95% CI, 3 to 18)
(P = 0.73) during the follow-up.
Treatment strategies used between 2 to 11 years were
reported previously [11]. In both groups, the patients in
the tertile of the lowest radiologic progression in hands
and feet from year 2 to year 11 (change in Larsen score, 0
to 1) had received significantly shorter periods of combi-
nation-DMARD treatments between years 2 and 11 than
did the patients with intermediate (change in Larsen
score, 2 to 17) or high (change in Larsen score, ≥18) pro-
gression rates (P = 0.001 for linearity in both treatment
groups) (Figure 4). A similar trend was found for biologic
treatments in the entire study population; 14 patients
(11%) had received TNF-inhibitors; of these, one had low;
five, intermediate; and eight, high radiographic progres-
sion between years 2 and 11.
Discussion
The main finding of the present study is that targeting to
remission with traditional DMARDs and tight clinical
controls results in low radiologic progression in most RA
patients. Still, patients treated initially with the FIN-
RACo strategy during the first 2 years have less radio-
graphic damage in small joints, even in long term than
did those treated initially with DMARD monotherapy.
Less radiographic damage is found in RA patients at
present than during previous decades [13]. In our study,
both treatment arms had excellent radiologic small-joint
outcome compared with historic cohorts. In a previous
Finnish cohort of 103 patients with early RA, beginning
in the 1970 s, the radiologic progression was steepest
Figure 1 The cumulative percentage of increase in Larsen score 
from baseline to 11 years in patients initially randomized to re-
ceive a combination (FIN-RACo) of disease-modifying antirheu-
matic drugs (DMARDs) or a single DMARD (SINGLE).
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Figure 2 The crude mean Larsen scores of hands and feet at baseline and at 2, 5, and 11 years in patients initially randomized to receive a 
combination (FIN-RACo) of disease-modifying antirheumatic drugs (DMARDs) or a single DMARD (SINGLE). (a) Included are the subjects 
scored at 11 years (two patients in each group did not have scores at 5 years). Values are expressed as the mean and 95% confidence interval. (b) The 
mean changes in Larsen score during years 0 to 2, 2 to 5, and 5 to 11, according to the initial treatment groups.
Table 1: Ordered logistic regression analysis for radiologic progression at 11 years
Variable at baseline Odds ratio (95% CI) P value
Female sex 1.74 (0.84 to 3.60) 0.13
Age, years 0.99 (0.96 to 1.02) 0.60
Disease duration before diagnosis, months 1.02 (0.94 to 1.10) 0.68
Rheumatoid factor positivity 3.17 (1.45 to 6.92) 0.004
Erythrocyte sedimentation rate 1.01 (0.99 to 1.02) 0.33
Larsen score 0.99 (0.94 to 1.05) 0.77
Initial randomization group 0.016
FIN-RACo 1.00 (reference)
SINGLE 2.39 (1.78 to 4.84)
Radiologic progression in hands and feet was determined according to the tertiles of Larsen score changes (categories 0 to 1, 2 to 17, and 
≥18). FIN-RACo, study group treated for the first 2 years with a combination of three disease-modifying antirheumatic drugs, initially 
methotrexate, sulfasalazine, and hydroxychloroquine, with prednisolone; SINGLE, study group treated for the first 2 years with one disease-
modifying antirheumatic drug, initially sulfasalazine, with or without prednisolone.
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low-up of 20 years [1]. In that cohort, the mean ± SD Lar-
sen score at 3 years was 27 ± 21, and at 15 years, 78 ± 49.
Thus, after 3 years of RA, the historic patients had com-
parable amounts of radiographic damage to the patients
of the present study at 11 years. In a Swedish cohort start-
ing in 1985, 181 patients with conservatively treated early
RA had, at 10 years, a median Larsen score of 54 (IQR, 28
to 80) [2], thus double the Larsen score of our patients at
11 years. These findings are in accordance with those of
Finckh et al. [13], who found that the radiographic prog-
nosis of RA has improved during the past decades parallel
to more active treatments.
Even though most patients had excellent radiographic
results at 11 years, the patients treated with the FIN-
RACo strategy had significantly lower increases in the
median Larsen score from baseline to 11 years than did
the SINGLE patients, and besides the presence of rheu-
matoid factor, only the initial SINGLE treatment pre-
dicted the radiographic progression at 11 years in the
ordered logistic regression analysis. The main difference
between the groups had developed during the first 2
years; after that, both groups progressed similarly. For
unknown reasons, the dropout patients in the FIN-RACo
group had a higher Larsen score at baseline than did
those cases who completed the study. Thus, in the com-
pleters of the FIN-RACo group, a trend toward a lower
Larsen score at baseline was seen compared with the
SINGLE group completers. At worst, this fact may bias
the study. However, in the statistical analysis adjusted
with baseline Larsen score, a highly significant difference
in radiologic progression was found between the groups.
Therefore, we find it justified to conclude that the
observed difference between the groups represents rather
the results of a more-effective initial DMARD treatment
strategy than a biologic bias.
For evaluating the radiographic damage, we used the
Larsen score, which has been found to be less sensitive to
change than the Sharp/van der Heijde method [14,15].
Conversely, the Larsen method tends to be more specific
than the Sharp/van der Heijde method [14], and when the
follow up is as long as 11 years, we prefer specificity over
sensitivity; it is more important to distinguish clinically
relevant from unspecific changes than to find subtle
joint-space narrowing. Also, the intraobserver reliability
in Larsen score is somewhat better than that of the
Sharp/van der Heijde method [15,16], and because we
have had the same experienced radiologist scoring the
radiographs with the Larsen method throughout the fol-
low-up, we find this method logical. To our knowledge,
no other methods exist for evaluating the radiographic
progression in large joints besides the Larsen method.
Only 13% of the FIN-RACo and 28% of the SINGLE
patients had some radiographic damage in large joints.
Few long-term studies of early RA assess large-joint dam-
age, and none of them have a definite treatment protocol.
One study, published in 1997, found radiographic damage
in large joints in 50% of the patients after 6 years of RA
[17]. In a Dutch study, 54% of patients had at least one
eroded large joint after 12 years of RA [18]. In the present
study, the infrequent destruction of large joints was also
reflected in the small number of total joint replacements
in both of our treatment groups compared with earlier
cohorts [19], even though the follow-up of 11 years is too
short to evaluate the final incidence of total joint replace-
ments.
Probably the most important precondition to our excel-
lent results in most patients was the active treatment pol-
icy aiming at remission at all time points. Even though
recent reports showed that radiologic progression may
occur even while the patient appears to be in remission
[20], most damage still emerges in clinically inflamed
joints [21]. Our results emphasize the importance of early
remission for the long-term outcome of the patients. In
the present study, the patients who had been in strict
remission at 1 year had significantly less radiologic pro-
Figure 3 The crude mean Larsen scores of hands and feet at base-
line, and at 2, 5, and 11 years in patients who had been in remis-
sion at 1 year and in patients who had not been in remission at 1 
year. Included are the subjects scored at 11 years (two patients in each 
group did not have scores at 5 years). Values are expressed as the mean 
and 95% confidence interval.
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who had not reached remission at 1 year. Remissions
were reached more often by the FIN-RACo arm patients
than by the SINGLE patients at 2 years [3], as well as at 11
years [11], but patients in both treatment arms had
mainly low disease activity and well-preserved function
throughout the follow-up [11]. This clinical profile fits
the radiologic profile of our study groups well; compared
with less aggressively treated patients, both groups were
doing well, but the FIN-RACo patients even better.
We earlier reported that during the liberal treatment
phase between years 2 and 11, the use of DMARDs dif-
fered between groups, with combination treatments used
more often in the original FIN-RACo group [11]. This
difference had, however, no impact on the clinical out-
come at 11 years. In the FIN-RACo group, the patients
who had low disease activity at 11 years had received sig-
nificantly shorter periods of combination DMARDs
between 2 and 11 years than had the patients who had
high disease activity at 11 years [11]. Similarly, in the
present study, the patients with the least radiologic pro-
gression after year 2 had received the shortest periods of
combination DMARD strategy after 2 years. These
results are in agreement with the fact that in longitudinal
observational studies, the cases treated most intensively
are the most likely ones to have the most severe disease
[22]. And yet, aggressive treatments in established disease
do not seem to gain as much effect as they do in early dis-
ease. This emphasizes the importance of early, effective
treatment and tight control of therapeutic response. Late
strengthening of DMARD treatment is not able to reverse
the damage already arisen. Nevertheless, it is probable
that radiologic progression would have been even steeper
had the treatments during the liberal phase been less
aggressive.
Glucocorticoids were a part of the FIN-RACo strategy
and were allowed in the SINGLE strategy to reach remis-
Table 2: Number (percentage) of RA patients with damage to any or to multiple large joints as well as with uni- or bilateral 
erosive (Larsen score ≥2) large joints after 11 years of follow-up, by initial randomization group
Original randomization group
FIN-RACo (n = 52) SINGLE (n = 54)
Damage to any large joint 7 (13%) 15 (28%)
Damage to multiple (two to three) large joints 5 (10%) 10 (19%)
Radiographed joint Unilateral damage Bilateral damage Unilateral damage Bilateral damage
Shoulder 0 2 (4%) 4 (7%) 7 (13%)
Elbow 1 (2%) 0 1 (2%) 1 (2%)
Hip 3 (6%) 2 (4%) 4 (7%) 1 (2%)
Knee 3 (6%) 1 (2%) 2 (4%) 0
FIN-RACo, study group treated for the first 2 years with a combination of three disease-modifying antirheumatic drugs, initially methotrexate, 
sulfasalazine, and hydroxychloroquine, with prednisolone; RA, rheumatoid arthritis; SINGLE, study group treated for the first 2 years with one 
disease-modifying antirheumatic drug, initially sulfasalazine, with or without prednisolone.
Figure 4 Percentage of treatment time using combination 
DMARD strategy between year 2 and year 11 in patients of the 
original randomization groups divided into tertiles, according to 
change in Larsen score of hands and feet from year 2 to year 11. 
Values are expressed as median and interquartile range.
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radiologic progression [5], it could be hypothesized that
their use would explain the difference in Larsen score
between the groups. However, the patients treated with
the FIN-RACo strategy needed fewer intraarticular glu-
cocorticoid injections and had a smaller cumulative dose
of glucocorticoids during the first 2 years than did the
SINGLE strategy group [3]. Thus, the better radiologic
outcome in the FIN-RACo arm does not seem to depend
on the use of glucocorticoids, but rather on the more
effective and rapidly working DMARDs during the criti-
cal "window of opportunity." Whether the difference
between the groups would have been smaller, had the
first DMARD in the SINGLE strategy been methotrexate,
cannot be answered by this study. However, the SINGLE
strategy was not tied to sulfasalazine but to a strategy of
using one DMARD at a time, and, during the first 2 years,
52% of patients in the SINGLE group were switched to
methotrexate [3].
Conclusions
We conclude that treating RA from the very beginning
actively and aggressively with DMARDs, including tight
clinical control and aiming for remission, pays off, even in
the long run. Further, the patients treated initially with
the FIN-RACo strategy manage better than the cases
treated actively with the SINGLE strategy. Both small and
large peripheral joints are spared. Consequently, the need
for joint-replacement operations decreases. Clinical dis-
ease activity remains low, functional capacity well pre-
served, and life expectancy normal [11]. Further studies
will reveal whether all this is reflected in the maintenance
of working capacity.
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